Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder
The Next Frontier: Innovations in Long-Acting Antipsychotic Treatment With innovative treatments like ERZOFRI® revolutionizing the management of schizophrenia and schizoaffective disorder, the future of long-acting injectable (LAI) therapies looks promising. This once-monthly, paliperidone palmitate-based medication exemplifies the advancements in simplifying treatment regimens, addressing both efficacy and patient adherence. Enhanced Treatment Adherence through Simplified Regimens Medication … Read more